Jérémie Nsengimana

Jérémie Nsengimana

Senior Lecturer in Biostatistics

Population Health Sciences Institute

Biography

Background

Jérémie Nsengimana is Senior Lecturer in Biostatistics in the Population Health Sciences Institute, Faculty of Medical Sciences. He holds a PhD from the Université Catholique de Louvain, Belgium (UCLLouvain) and has previously worked at the University of Leeds School of Medicine, Leeds, UK (Research Fellow / Senior Statistician, 2004-2020) and the International Agency for Research on Cancer, Lyon, France (Postdoctoral Research Fellow, 2003-2004). Jérémie’s research focuses on efficient analysis of preclinical studies with a particular interest in biomarker and drug target discovery. He is a member of the TEsticular CAncer Consortium (TECAC) and the Melanoma Genetics Consortium (GenoMEL).

Supervised PhDs

  • Dr Rohit Thakur (2015-19): Developing statistical and bioinformatic analysis of genomic data from tumours
  • Dr Joanna Poźniak (2015-19): Transcriptomic variation in primary melanoma in immunological pathways related to survival
  • Lucy Godson (2020-): Machine learning integration of molecular and imaging data in cancer outcome prediction

Research

Efficient analysis of preclinical studies.

Scopus: Click here

Teaching

Postgraduate Medical Statistics & Project Supervision.

Contact

Publications

Quickly discover relevant content by filtering publications.
Isabella Harumi Yonehara Noma, Larissa Anastacio da Costa Carvalho, Denisse Esther Mallaupoma Camarena, Renaira Oliveira Silva, Manoel Oliveira de Moraes Junior, Sophia Tavares de Souza, Julia Newton-Bishop, Jérémie Nsengimana, Silvya Stuchi Maria-Engler (2024). Peroxiredoxin-2 represses NRAS-mutated melanoma cells invasion by modulating EMT markers. Biomedicine & Pharmacotherapy.

Cite DOI URL

Lucy Godson, Navid Alemi, Jérémie Nsengimana, Graham P. Cook, Emily L. Clarke, Darren Treanor, D. Timothy Bishop, Julia Newton-Bishop, Ali Gooya, Derek Magee (2024). Immune subtyping of melanoma whole slide images using multiple instance learning. Medical Image Analysis.

Cite DOI URL

Svetlana Cherlin, Theophile Bigirumurame, Michael J Grayling, Jérémie Nsengimana, Luke Ouma, Aida Santaolalla, Fang Wan, S Faye Williamson, James MS Wason (2023). Utilising high-dimensional data in randomised clinical trials: A review of methods and practice. Research Methods in Medicine & Health Sciences.

Cite DOI URL

Chiara Grasso, Maja Popovic, Elena Isaevska, Fulvio Lazzarato, Valentina Fiano, Daniela Zugna, John Pluta, Benita Weathers, Kurt D′Andrea, Kristian Almstrup, Lynn Anson-Cartwright, D. Timothy. Bishop, Stephen J. Chanock, Chu Chen, Victoria K. Cortessis, Marlene D. Dalgaard, Siamak Daneshmand, Alberto Ferlin, Carlo Foresta, Megan N. Frone, Marija Gamulin, Jourik A. Gietema, Mark H. Greene, Tom Grotmol, Robert J. Hamilton, Trine B. Haugen, Russ Hauser, Robert Karlsson, Lambertus A. Kiemeney, Davor Lessel, Patrizia Lista, Ragnhild A. Lothe, Chey Loveday, Coby Meijer, Kevin T. Nead, Jérémie Nsengimana, Rolf I. Skotheim, Clare Turnbull, David J. Vaughn, Fredrik Wiklund, Tongzhang Zheng, Andrea Zitella, Stephen M. Schwartz, Katherine A. McGlynn, Peter A. Kanetsky, Katherine L. Nathanson, Lorenzo Richiardi (2022). Association study between polymorphisms in DNA methylation-related genes and testicular germ cell tumor risk. Cancer Epidemiology, Biomarkers &$mathsemicolon$ Prevention.

Cite DOI URL

María Victoria Castro, Gastón Alexis Barbero, Paula Máscolo, María Belén Villanueva, Jérémie Nsengimana, Julia Newton-Bishop, Edith Illescas, María Josefina Quezada, Pablo Lopez-Bergami (2022). ROR2 promotes epithelial-mesenchymal transition by hyperactivating ERK in melanoma. Journal of Cell Communication and Signaling.

Cite DOI URL

Carolina Castaneda-Garcia, Vivek Iyer, Jérémie Nsengimana, Adam Trower, Alastair Droop, Kevin M Brown, Jiyeon Choi, Tongwu Zhang, Mark Harland, Julia A Newton-Bishop, D Timothy Bishop, David J Adams, Mark M Iles, Carla Daniela Robles-Espinoza (2022). Defining novel causal SNPs and linked phenotypes at melanoma-associated loci. Human Molecular Genetics.

Cite DOI URL

Debora D'Angelo Papaiz, Flávia Eichemberger Rius, Ana Luísa Pedroso Ayub, Clarice S. Origassa, Hemant Gujar, Diogo de Oliveira Pessoa, Eduardo Moraes Reis, Jérémie Nsengimana, Julia Newton-Bishop, Christopher E. Mason, Daniel J. Weisenberger, Gangning Liang, Miriam Galvonas Jasiulionis (2022). Genes regulated by DNA methylation are involved in distinct phenotypes during melanoma progression and are prognostic factors for patients. Molecular Oncology.

Cite DOI URL

Nathaniel R. Campbell, Anjali Rao, Miranda V. Hunter, Magdalena K. Sznurkowska, Luzia Briker, Maomao Zhang, Maayan Baron, Silja Heilmann, Maxime Deforet, Colin Kenny, Lorenza P. Ferretti, Ting-Hsiang Huang, Sarah Perlee, Manik Garg, Jérémie Nsengimana, Massimo Saini, Emily Montal, Mohita Tagore, Julia Newton-Bishop, Mark R. Middleton, Pippa Corrie, David J. Adams, Roy Rabbie, Nicola Aceto, Mitchell P. Levesque, Robert A. Cornell, Itai Yanai, Joao B. Xavier, Richard M. White (2021). Cooperation between melanoma cell states promotes metastasis through heterotypic cluster formation. Developmental Cell.

Cite DOI URL

Pluta J, Pyle LC, Nead KT, Wilf R, Li M, Mitra N, Weathers B, D’Andrea K, Almstrup K, Anson-Cartwright L, Benitez J, Brown CD, Chanock S, Chen C, Cortessis VK, Ferlin A, Foresta C, Gamulin M, Gietema JA, Grasso C, Greene MH, Grotmol T, Hamilton RJ, Haugen TB, Hauser R, Hildebrandt MAT, Johnson ME, Karlsson R, Kiemeney LA, Lessel D, Lothe RA, Loud JT, oveday C, Martin-Gimeno P, Meijer C, Nsengimana J, Quinn DI, Rafnar T, Ramdas S, Richiardi L, Skotheim RI, Stefansson K, Turnbull C, Vaughn DJ, Wiklund F, Wu X, Yang D, Zheng T, Wells AD, Grant SFA, Rajpert-De Meyts E, Schwartz SM, Bishop DT, McGlynn KA, Kanetsky PA, Nathanson KL, The Testicular Cancer Consortium (2021). Identification of 22 susceptibility loci associated with testicular germ cell tumors. Nat Commun 2021; 12:4487.

DOI

Bi O, Anene CA, Nsengimana J, Shelton M, Roberts W, Newton-Bishop J, Boyne JR (2021). SFPQ promotes an oncogenic transcriptomic state in melanoma. Oncogene 2021; 40:5192-5203.

DOI

Polubothu S, Zecchin D, Al-Olabi L, Lionarons DA, Harland M, Horswell S, Thomas AC, Hunt L, Wlodarchak N, Aguilera P, Brand S, Bryant D, Carrera C, Chen H, Elgar G, Harwood CA, Howell M, Larue L, Loughlin S, MacDonald J, Malvehy J, Martin Barberan SM, Martins da Silva V, Molina M, Morrogh D, Moulding D, Nsengimana J, Pittman A, Puig-Butillé J-A, Parmar K, Sebire NJ, Scherer S, Stadnik P, Stanier P, Tell G, Waelchli R, Zarrei M, Puig S, Bataille V, Xing Y, Healy E, Moore GE, Di W-L, Newton-Bishop J, Downward J, Kinsler VA (2021). Inherited duplications of PPP2R3B predispose to nevi and melanoma via a C21orf91-driven proliferative phenotype. Genet Med 2021; DOI:10.1038/s41436-021-01204-y.

DOI

de Oliveira Pessoaa D, Eichemberger Rius F, D'Angelo Papaiz D, Pedroso Ayub AL, Santana Morais A, Ferreira de Souza C, Ferreira da Paixão V, Carlos Setubal J, Newton-Bishop J, Nsengimana J, Azevedo H, Moraes Reis E, Galvonas Jasiulionis M (2021). Transcriptional signatures underlying dynamic phenotypic switching and novel disease biomarkers in a linear cellular model of melanoma progression. Neoplasia 2021; 23:439-55.

DOI

Juraleviciute M, Nsengimana J, Newton-Bishop J, Hendriks GJ, Slipicevic A (2021). MX2 mediates establishment of interferon response profile, regulates XAF1, and can sensitize melanoma cells to targeted therapy. Cancer Med 2021; doi:10.1002/cam4.3846.

DOI

Garg M, Couturier D-L, Nsengimana J, Fonseca NA, Wongchenko M, Yan Y, Lauss M, Jönsson GB, Newton-Bishop J, Parkinson C, Middleton MR, Bishop T, McDonald S, Stefanos N, Tadross J, Vergara IA, Lo S, Newell F, Wilmott JS, Thompson JF, Long GV, Scoyler RA, Corrie P, Adams DJ, Brazma A, Rabbie R (2021). Tumour gene expression signature in primary melanoma predicts long-term outcomes. Nature Commun 2021; 12:1137.

DOI

Shelton M, Anene CA, Nsengimana J, Roberts W, Newton-Bishop J, Boyne JR (2020). The role of CAF derived exosomal microRNAs in the tumour microenvironment of melanoma. BBA - Rev Cancer 2021; 1875:188456.

DOI

Campbell NR, Rao A, Zhang M, Baron M, Heilmann S, Deforet M, Kenny C, Ferretti L, Huang T-H, Garg M, Nsengimana J, Montal E, Tagore M, Hunter M, Newton-Bishop J, Middleton MR, Corrie P, Adams DJ, Rabbie R, Levesque MP, Cornell RA, Yanai I, Xavier JB, White RM (2020). Cell state diversity promotes metastasis through heterotypic cluster formation in melanoma. bioRxiv 2020; DOI:10.1101/2020.08.24.265140.

DOI

Azevedo H, Cavalcante Pessoa G, de Luna Vitorino FN, Nsengimana J, Newton-Bishop J, Moraes Reis E, Pinheiro Chagas da Cunha J, Galvonas Jasiulionis M (2020). Gene co-expression and histone modification signatures are associated with melanoma progression, epithelial-to-mesenchymal transition, and metastasis. Clin Epigenetics 2020; 12:127.

DOI

Al Emran A, Nsengimana J, Punnia-Moorthy G, Schmitz U, Gallagher SJ, Newton-Bishop J, Tiffen JC, Hersey P (2020). Study of the female sex survival advantage in melanoma--A focus on X-linked epigenetic regulators and immune responses in two cohorts. Cancers 2020; 12:2082.

DOI

Maurichi A, Miceli R, Eriksson H, Newton-Bishop J, Nsengimana J, Chan M, Hayes AJ, Heelan K, Adams D, Patuzzo R, Barretta F, Gallino G, Harwood C, Bergamaschi D, Bennett D, Lasithiotakis K, Ghiorzo P, Dalmasso B, Manganoni A, Consoli F, Mattavelli I, Barbieri C, Leva A, Cortinovis U, Espeli V, Mangas C, Quaglino P, Ribero S, Broganelli P, Pellacani G, Longo C, Del Forno C, Borgognoni L, Sestini S, Pimpinelli N, Fortunato S, Chiarugi A, Nardini P, Morittu E, Florita A, Cossa M, Valeri B, Milione M, Pruneri G, Zoras O, Anichini A, Mortarini R, Santinami M (2020). Factors affecting sentinel node metastasis in thin (T1) cutaneous melanomas: Development and external validation of a predictive nomogram. J Clin Oncol 2020; 38:1591-601.

DOI

Close HJ, Stead LF, Nsengimana J, Reilly KA, Droop A, Wurdak H, Mathew RK, Corns R, Newton-Bishop J, Melcher AA, Short SC, Cook GP, Wilson EB (2019). Expression profiling of single cells and patient cohorts identifies multiple immunosuppressive pathways and an altered NK cell phenotype in glioblastoma. Clin Exp Immunol 2019; 200:33-44.

DOI

See all publications